Trial Profile
Phase II study of Nivolumab in patients with relapsed/refractory hematologic malignancies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Haematological malignancies; Myelodysplastic syndromes; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms NIVOMAT
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.
- 05 Sep 2018 New trial record